Conflicts of Interest. I have no conflicts of interest regarding this presentation

Transcription

1 Conflicts of Interest I have no conflicts of interest regarding this presentation

2 Ramon Ylanan MD CAQSM Team Physician University of Arkansas Advanced Orthopeadic Specialists

3 Goals Background Healing Response The Basic Science Uses Evidence Based Summary

4 Goals Background Healing Response The Basic Science Uses Evidence Based Summary

5 Background What is PRP (Platelet Rich Plasma)? Biologic, regenerative biomedicine Concentrated platelets Ideally 3-8X Processed from autologous, whole blood Provides Supra-physiologic concentrations of growth factors No universal definition of what constitutes PRP vs PPP Ideal concentration is opinion based

6 Background How is it made? Centrifuged whole blood Coagulation inhibitors may be used Previous issues with bovine inhibitors Platelet activators may be used Volume produced depends on which system used Applied in either Injectable form Solid, matrix form

7 Background System Platelet Conc. Activator Centrifuge time Leukocytes Blood Volume needed (ml) PRP volume Arthrex ACP 2-3X No (use within 30 minutes) Biomet GPS III 3-8x Autologous thrombin and calcium chloride 1, 5 min step No 9 3 1, 15 minute step Yes Cascade 1-1.5x Calcium chloride 1, 6 minute for PRP 2, 15 minute for fibrin matrix No SmartPReP2 4-6x Bovine thrombin or calcium 2, 14 minute step Yes PRGF 2-3x Calcium chloride 1, 8 minute step No Magellan 3-7x Calcium chloride 2, 4-6 minute steps Yes

8 Goals Background Healing Response The Basic Science Uses Evidence Based Summary

9 Background: The Healing Response Inflammatory phase First week after injury Hemostasis recruitment of macrophages and fibroblasts Proliferative phase Within first 2 days to 2 weeks Formation of extra-cellular scaffold Maturation/remodeling phase Up to first year Type 1 collagen replacing scaffold

10 Background: The Healing Response Growth factors IGF-1 early inflammatory phase Enhances collagen and matrix synthesis TGF-B pro-inflammatory Enhances matrix and collagen synthesis, angiogenesis PDGF facilitates proliferation of other growth factors Attracts stem cells and contributes to remodeling

11 Background: The Healing Response Growth factors VEGF peaks after inflammatory phase Promotes angiogenesis and neovascularization b-fgf angiogenesis, cell migration, creates collagenase, production of granulation tissue

12 Background: The Healing Response What does PRP bring to the healing table? Alpha granules The storage packets of growth factors Each platelet contains granules The de-granulation releases the growth factors needed to augment healing

13 Background: The Healing Response Alpha granules Theory that activators will increase degranulation Reason why some systems include external activators Some studies show injured collagen fibers will stimulate de-granulation as well

14 Goals Background Healing Response The Basic Science Uses Limit to Muscle, Tendon, Ligament Evidence Based Summary

15 The Basic Science Horse tendons Schnabel et al. Culture in PRP vs other blood products Higher anabolic gene expression in PRP Human tenocytes de Mos et al. PRP vs. PPP PRP increase in matrix degrading enzymes (faster recovery)

16 The Basic Science Rabbit skeletal muscle stem cells Gates et al. Increased expression of myogenic activity Mesenchymal stem cells Mishra et al. Buffered in PRP, increased proliferation

17 Goals Background Healing Response The Basic Science Uses Limit to Muscle, Tendon, Ligament Evidence Based Summary

18 Uses: Muscle Hammond et al (2009) Animal study (rats) Tibialis anterior strain large strain vs small strain PRP shortened healing by days in small strain group Little change in large strain group

19 Uses: Tendon Lots of studies Lateral epicondylitis Patellar tendinopathy Achilles tendinopathy Rotator Cuff tendinopathy

20 Uses: Lateral Epicondylitis

21 Uses: Lateral Epicondylitis Mishra and Pavelko (2006) One of the most cited articles Chronic, refractory lateral epicondylitis 15 patients, failed conservative measures Single PRP injection control was bupivicaine

22 Uses: Lateral Epicondylitis Mishra and Pavelko (2006) Measures VAS and Mayo elbow scores at 2, 6 and 25 months Outcomes 2 months 60% vs 16% improvement (P=.001) Final f/u 93% reduction in pain, no complications 60% of control group withdrew for other treatment

23 Uses: Lateral Epicondylitis Peerbooms et al (2010) RCT, Level 1 data Only true RCT to date 100 patients (51 PRP:49 CSI) 1 yr f/u 73% success in PRP group 49% in CSI group

24 Uses: Patellar Tendinopathy

25 Uses: Patellar Tendinopathy Human Data is limited Filardo et al (2010) Non-RCT, N=31 Serial PRP + PT (15) vs. PT alone (16) 3 PRP, 2 weeks apart with eccentric strengthening PRP group Improved in all measures Continued to improve at 6 months Higher improvement in sports activity

26 Uses: Patellar Tendinopathy Kon et al (2009) Prospective, pilot study (no control) 3 PRP injections, 15 days apart 6 month f/u 70% stated complete or significant improvement 80% satisfied with results

27 Uses: Achilles Tendinopathy

28 Uses: Achilles Tendinopathy de Vos et al (2010) Double blinded, placebo control, RCT N=54, chronic Achilles tendinopathy 2 months of symptoms Excluded if had previous eccentric strengthening program 27 PRP, 27 isotonic saline, US guidance used

29 Uses: Achilles Tendinopathy de Vos et al (2010) Double blinded, placebo control, RCT N=54, chronic Achilles tendinopathy Both did 12 week supervised eccentric program f/u at 6, 12, 24 weeks - Both groups improved, No difference found - Used bupivicaine for anesthetic -? Inhibit effectiveness

30 Uses: Rotator Cuff Mostly as surgical repair adjuncts Studies have been +/- Only one major prospective, Level 1 randomized research Weber et al (2010) No major difference in structural integrity compared with control Repair with PRP vs repair without PRP

31 Uses: MCL No human studies Letson and Dahners (1994) Rat MCL injury Injected with PDGF 73% (+/- 55%) stronger than contralateral controls Human results anecdotal 2-3 weeks earlier than anticipated

32 Goals Background Healing Response The Basic Science Uses Limit to Muscle, Tendon, Ligament Evidence Based Summary

33 What does the evidence say? Increasing number of basic science and animal studies Paucity of human trials No standardization of treatment Anecdotally improves recovery by 2 weeks 1 vs. multiple injections 1 seems to be effective, fenestration may help The multiple injection protocol is without consistency

34 What does the evidence say? When is best time to administer in acute setting? Chan et al Better results at day 7 than day 3 At elite level, who waits 7 days?

35 What does the evidence say? Exercise Early ROM can be helpful Early light aerobic activity can be helpful I begin eccentric strengthening program as early as tolerated Goal is RTP by 3 weeks

36 What does the evidence say? NSAIDs Most hold for minimum of 10 days prior Not proven to inhibit, but possible Don t withhold ASA if cardio-protective Ideal platelet concentration 600K-1mil per ml (no evidence for that)

37 What does the evidence say? WBC in preparation Inhibit or help? Help anti-infective property Inhibit inhibitory effects on inflammatory mediators

38 What does the evidence say? Local anesthetics and corticosteroids Carofino et al (2012) Co-administration decreased PRP effectiveness External platelet activators No consensus on if or when

39 What does the evidence say? MSK US guidance improves results 0232T tracking CPT code Includes imaging assisted guidance I use it with every PRP

40 Where are we with PRP?

41 Summary Limited human research Tendon>Muscle>Ligament for now Limit NSAID use around the injection Don t add local anesthetic Still more to learn Medicare tracking code now IOC had banned it in 2010, removed in 2011

42 References Nguyen RT, Borg-Stein J, McInnis, K. Applications of Platelet-Rish Plasma in Musculoskeletal and Sports Medicine: An Evidence-Based Approach. PM R 2011;3: Schnabel LV, Mohammed HO, Miller BJ, et al. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. J Orthop Res 2007;25: de Mos M, van der Windt AE, Jahr H, et al. Can platelet-rich plasma enhance tendon repair? A cell culture study. Am J Sports Med 2008; 36: Mishra A, Tummala P, King A, et al. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods 2009;15: Gates CB, Karthikeyan T, Fu F, Huard J. Regenerative medicine for the musculoskeletal system based on muscle-derived stem cells. J Am Acad Orthop Surg 2008;16: Hammon JW, Hinton RY, et al. Use of autologous platelet-rich plasma to treat muscle strain injuries. Am J Sports Med 2009;37: Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med 2006;34: Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double- blind randomized controlled trial: Platelet-rich plasma versus cortico- steroid injection with a 1-year follow-up. Am J Sports Med 2010;38: Filardo G, Kon E, Della Villa S, Vincentelli F, Fornasari PM, Marcacci M. Use of platelet-rich plasma for the treatment of refractory jumper s knee. Int Orthop 2010;34: Kon E, Filardo G et al. Platelet-rich plasma: New clinical application: A Pilot study for treatment of jumper s knee. Injury 2009;40: de Vos RJ, Weir A, van Schie HT, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: A randomized controlled trial. JAMA 2010;303: WeberSC,PariseC,KatzSD,WeberSJ.Platelet-richfibrin-membrane in arthroscopic rotator cuff repair: A prospective, randomized study. Proc Am Acad Orthop Surg 2010;11:345. Weber SC, Katz SD, Parise C, Weber SJ. Platelet-rich fibrin matrix in the management of arthroscopic repair of the rotator cuff: A prospec- tive, randomized study (SS-07). Arthroscopy 2010;26:e4. Carofino B, Chowaniec Dm, et al. Corticosteroids and local anesthetics decrease positive effects of platelet-rich plasma: an in vitro study on human tendon cells. Arthroscopy May;28(5):711-9 Engebreatsen L, Steffen K et al. IOC consensus paper on the use of platelet-rich plasma in sports medicine. BJSM 2010;44: